Skip to main content
Marina Kremyanskaya, MD, Oncology, New York, NY

MarinaKremyanskayaMD

Oncology New York, NY

Hematologic Oncology

Assistant Professor, Medicine, Icahn School of Medicine at Mount Sinai

Dr. Kremyanskaya is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kremyanskaya's full profile

Already have an account?

  • Office

    10 E 102nd St
    New York, NY 10029
    Phone+1 212-241-6756
    Fax+1 212-731-5210

Education & Training

  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2006 - 2009
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2006

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2026
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF). 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021
    Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021May 12th, 2021
  • Hepcidin Mimetic Eliminates Need for Phlebotomy in Polycythemia Vera
    Hepcidin Mimetic Eliminates Need for Phlebotomy in Polycythemia VeraDecember 18th, 2020
  • Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting
    Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual MeetingNovember 4th, 2020
  • Join now to see all